comprehensive -WSS

comprehensive

author：explore 2025-09-27 22:56:37 - browse：2442

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： How a symptom of dementia informs our understanding of creativity

WSS

Medicare bonuses could stop drug shortages under Senate plan

Neuroscience startup Neumora files for IPO

Cardiologists urge adding sexual orientation, gender identity to health records

Complete sequence of Y chromosome published for first time

There's an unseen cost to disruptive road

Inaction leaves children at risk from dangerous chemotherapy drug

Wikipedia

comprehensive

focus

How one medical school became remarkably diverse

Flu vaccine reformulation won't be easy, manufacturers warn

The cancer drug shortage isn’t new — and neither are the solutions

Flu vaccine reformulation won't be easy, manufacturers warn

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

To bolster infectious disease surveillance, genomics powerhouses team up

At least 13 dead in Texas as scorching temps continue

Medicare bonuses could stop drug shortages under Senate plan

Moonlake's readout produced a cash windfall. Risks remain

Feds fine Medicare Advantage plans for overcharging members

explore

Inaction leaves children at risk from dangerous chemotherapy drug

HPV vaccine, cervical cancer study delivers historic results

Cardiologists urge adding sexual orientation, gender identity to health records

What causes osteoarthritis? Researchers study link to brain protein

TikTok, Instagram influencers need more rules for drug ads

AstraZeneca challenges Medicare drug negotiation program

Wikipedia

hotspot

Wikipedia

explore